Abstract
Dengue is known to exhibit focal clustering at the level of the household and neighbourhood, driven by local mosquito population dynamics, human population immunity, and fine scale human and mosquito movement. We tested the hypothesis that spatiotemporal clustering of homotypic dengue cases is disrupted by introduction of the arbovirus-blocking bacterium Wolbachia (wMel-strain) into the Aedes aegypti mosquito population in a randomized controlled trial in Yogyakarta, Indonesia. We analysed 318 serotyped dengue cases and 5,921 test-negative controls with geolocated residence enrolled over 27 months following randomized wMel deployments. We find evidence of spatial dependence up to 300m among the 265 dengue cases (3,083 controls) detected in the untreated trial arm. Spatial dependence is strongest within 50m, with a 4.7-fold increase (compared to 95% CI on permutation-based null distribution: 0.1, 1.2) in the odds that a pair of individuals enrolled within 30 days and 50m of each other are homotypic dengue cases compared to pairs occurring at any distance. We find no evidence of spatial dependence among the 53 dengue cases (2,838 controls) detected in the wMel-treated arm. This provides compelling evidence that introgression of wMel Wolbachia into Aedes aegypti mosquito populations interrupts focal dengue virus transmission, leading to reduced case incidence.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03055585
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03055585
Funding Statement
We gratefully acknowledge the Tahija Foundation as funders of the AWED trial, and the Wellcome Trust and the Bill and Melinda Gates Foundation, which provided financial support to the World Mosquito Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial protocol for the Applying Wolbachia to Eliminate Dengue (AWED) trial study was approved by the Universitas Gadjah Mada (UGM) ethics committee (approval number KE/FK/105/EC/2016) and Monash University Human Research Ethics Committee (approval number 0960). Written informed consent was obtained from participants (or their guardian where the participant is a minor). In addition, participants between 13 and 17 years of age were invited to sign a consent form indicating that they understood the research and agreed to participate.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos